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Abstract In the last few years, a lot of publications suggested
that disabling cerebellar ataxias may develop through
immune-mediated mechanisms. In this consensus paper, we
discuss the clinical features of the main described immune-
mediated cerebellar ataxias and address their presumed path-
ogenesis. Immune-mediated cerebellar ataxias include cere-
bellar ataxia associated with anti-GAD antibodies, the cere-
bellar type of Hashimoto’s encephalopathy, primary autoim-
mune cerebellar ataxia, gluten ataxia, Miller Fisher syndrome,
ataxia associated with systemic lupus erythematosus, and
paraneoplastic cerebellar degeneration. Humoral mechanisms,
cell-mediated immunity, inflammation, and vascular injuries
contribute to the cerebellar deficits in immune-mediated cer-
ebellar ataxias.
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Consensus Paper: Neuroimmune Mechanisms
of Cerebellar Ataxias
Introduction (H. Mitoma)
Historical Scope More and more evidence suggest that cere-
bellar ataxias (CAs) in some patients develop through
immune-mediated mechanisms. The involvement of
immune-mediated pathomechanisms in the etiology of CAs
was first proposed in the context of multiple sclerosis (MS). In
a well-cited lecture delivered in 1868 [1], J.M. Charcot de-
scribed the relapsing and remitting clinical course and the
pathology of demyelination. The same lecture also described
the presence of cerebellar symptoms, such as intention tremor,
scanning speech and nystagmus, in addition to those of optic
neuritis and paralysis. These cerebellar symptoms, which
were subsequently termed the Charcot’s triad, were consid-
ered to provide evidence for lesions in supraspinal structures.
Although CAs rarely occur in isolation during the first attack
(the reported incidence of CAs based on symptoms at presen-
tation was about 15 %), they are common in established MS
[2]. Based on the results of experimental allergic encephalo-
myelitis, the following cell-mediated mechanisms responsible
for myelin damage have been proposed [2]: (1) Lymphocytes
activated by antigens or those that present antigens, enter the
blood brain barrier, where they can recruit other immune cells,
and (2) lymphocyte-induced myelin damage is mediated
through the actions of certain substances, e.g., tumor necrosis
factor in plaques.
In MS, immune-mediated demyelination can occur in any
area of the central nervous system (CNS) white matter and,
consequently, in addition to ataxia there is a wide spectrum of
neurological symptoms. However, in the last years, many au-
thors described patients with the cerebellum as the sole target
of autoimmunity, such as paraneoplastic cerebellar
degeneration.
The first cases of paraneoplastic cerebellar degeneration
associated with an ovary carcinoma were reported in 1919
by Brouwer [3]. This was followed by the identification of
other cases associated with different kind of cancers such as
breast or lung carcinoma and the description of specific auto-
antibodies (anti-Yo) in patients with CAs and gynecological
cancer [4]. Since then, various autoantibodies have been iden-
tified depending on neoplasma or associated extracerebellar
symptoms [5]. Furthermore, seronegative types of
paraneoplastic cerebellar degenerations have also been report-
ed [5]. The association of cerebellar autoantibodies with CAs
suggests that autoimmunity triggered by the neoplasm results
in the development of CA-related symptoms.
In contrast to the well-establ ished concept of
paraneoplastic cerebellar degeneration, the clinical entity of
nonparaneoplastic immune-mediated CAs was only
established recently [6–8]. In the 1980s, these cases were re-
ported in association with autoantibodies, and three clinical
entities have been established so far, based on the kind of
the associated antibodies (Abs): CAwith Abs to glutamic acid
decarboxylase (GAD), CA with Abs to thyroid tissue (cere-
bellar type of Hashimoto’s encephalopathy), and CAwith Abs
to gliadin (gluten ataxia). The features characterizing these
entities are as follows: (1) positivity for antibodies in the se-
rum or cerebrospinal fluid (CSF); (2) mild or no atrophy of the
cerebellum on magnetic resonance imaging (MRI) at the early
stage; and, (3) improvement of CAs, at least in part, by im-
munotherapy or in the case of gluten ataxia strict adherence to
a gluten-free diet. In addition to these three subtypes, the con-
cept of primary autoimmune cerebellar ataxia (PACA) was
recently proposed as an additional immune-mediated CA
[9]. In PACA, the cerebellum is a primary target of autoim-
munity and is sometimes associated with cerebellar autoanti-
bodies. Recently, the association with Homer 3, ARHGAP26,
and ITPR1 antibodies was also reported [10–12].
The Concept of Brain Autoimmune Diseases In the last
10 years, different authors have identified that, in some pa-
tients with encephalitis, the disorders are immune mediated.
These patients may present complex neuropsychiatric symp-
toms such as deficits of memory, cognition, psychosis, sei-
zures, abnormal movements, or coma. These disorders affect
mainly young women, but also men and children, and are
potentially lethal but curable if promptly recognized and treat-
ed by immunomodulators. The most important discovery is
that these disorders occur in association with autoantibodies to
extracellular epitopes of receptors or proteins involved in syn-
aptic transmission and plasticity, such as voltage-gated potas-
sium channel complex (LGI1, CASPR2) [13, 14], AMPA
[15], NMDA [16] and GABAB [17] receptors. Some of these
patients develop a tumor and the syndrome can be qualified as
paraneoplastic [18], but most of the cases are idiopathic. In-
terestingly, many arguments suggest that associated autoanti-
bodies may play a direct role in the pathomechanisms of the
encephalitis. For example, autoantibodies directed to AMPA
and NMDA receptors decrease the numbers of these cell-
surface receptors (internalization), which could lead to behav-
ioral deficits [19–21]. Furthermore, autoantibodies to AMPA
receptor also act as agonists and increase cell excitability [22].
The above findings suggest that autoimmune mechanisms
play a role in the aetiopathology of such encephalitis.
Interestingly, the cerebellum and the hippocampus are two
brain regions preferentially targeted by autoimmunity. How-
ever, at this stage of our knowledge, immune-mediated CAs
appear to have more heterogeneous or diverse features with
respect to autoimmune pathogenesis, compared with autoim-
mune limbic encephalitis, which shows somewhat uniform
features with regard to the nature of antigens (localization
and role in cell physiology), induction of autoimmunity, and
perhaps, significance of autoantibodies.
Significance and Classification Although immune-mediated
CAs can be character ized as t reatable a tax ias ,
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immunotherapy seems to be effective only at the early stages
of the disease. On the other hand, accumulating evidence sug-
gests a higher than expected incidence of immune-mediated
CAs among sporadic CAs. Prospective studies by
Hadjivassiliou et al. [9] in the UK showed that the prevalence
of immune-mediated CAs was 32% in a group of 320 patients
with sporadic ataxia (gluten ataxia 27 %, paraneoplastic cere-
bellar degeneration 3 %, and anti-GAD-Abs associated CA
3 %). Taken together, clinicians are now required to establish
the diagnosis of immune-mediated CAs and to initiate immu-
notherapy at an early stage. For selection of adequate thera-
peu t i c s t r a t eg ies , a good unders tand ing of the
pathomechanisms of CAs is necessary.
When autoimmunity targets the cerebellum or its related
structures, immune-mediated CAs are classified according to
the trigger of autoimmunity [9] (Table 1). Immune-mediated
CAs in which autoimmunity is not clearly triggered by anoth-
er disease include anti-GAD-Abs associated CA, cerebellar
type of Hashimoto’s encephalopathy, and PACA. On the other
hand, immune-mediated CAs in which autoimmunity is trig-
gered by another disease include gluten ataxia, Miller Fisher
syndrome, and paraneoplastic cerebellar degeneration. These
diseases are triggered by gluten sensitivity, infection, or neo-
plasm, respectively.
Aim of this Consensus Paper The objective of this consen-
sus paper is to summarize the clinical features of each
immune-mediated CA entity in which the target of autoimmu-
nity is the cerebellum or its related structures, and address their
immune-mediated pathomechanisms. To this aim, we pre-
pared contributions from international experts involved in re-
search on various aspects of immune-mediated CAs, provid-
ing key concept in each subtopic. For comparative under-
standing of key concepts of clinical features and
pathomechanisms of each subtype of immune-mediated CA,
the experts have provided summaries on the current thinking
about immune-mediated CAs. Some newly emerging entities
such as Hashimoto’s encephalopathy and PACA have been
focuses of discussions and do not have widely accepted diag-
nostic criteria. In addition, diverse immune-mediated
pathomechansms have not been clarified yet. In this sense,
further research should be performed. However, we believe
that the present consensus will be valuable to clarify the topic
and trigger novel research.
Cerebellar Ataxia with Glutamic Acid
Decarboxylase Autoantibodies (B. Joubert and J.
Honnorat)
Glutamic acid decarboxylase (GAD) is the rate-limiting en-
zyme for the production of GABA (γ-aminobutyric acid), the
main inhibitory neurotransmitter in the CNS. GAD is expressed
in CNS GABAergic neurons and in the pancreatic islet β-cells
and exists as two isoforms, GAD65 and GAD67 [23]. The
soluble isoform GAD67, mainly expressed in the cytoplasm
of neurons, is suggested to regulate the basal levels of GABA
[24], while the shorter form GAD65 is associated with the cell
membrane at nerve terminals and is involved both in the syn-
thesis of GABA and its exocytosis at inhibitory synapses [25].
Anti-GAD65 antibodies (GAD-Ab) were first described in
type 1 diabetes mellitus (T1DM) patients, and are considered
as a biological marker of this disease. GAD-Ab have also been
reported in some patients with neurological diseases, such as
stiff person syndrome (SPS), cerebellar ataxia, limbic enceph-
alitis, abnormal eye movements, progressive encephalomyeli-
tis with rigidity and myoclonus and refractory epilepsy [26].
Cerebellar ataxia with GAD-Ab was initially described in
few case reports [27, 28] and in a series of 14 patients [6].
Although rare, this syndrome is now well established [26].
This disease affects mostly women in their sixth decade. Cer-
ebellar ataxia installs either insidiously or subacutely [6, 29]
and tends to progress continuously over time. Symptoms in-
clude mainly static ataxia, dysarthria, and nystagmus. Further-
more, cerebellar ataxia may coexist with SPS [29, 30], periph-
eral neuropathy, limb stiffness [6], andmyasthenia gravis [28].
A personal or familial history of other autoimmune diseases,
such as T1DM, hemolytic anemia or thyroiditis is frequent [6],
while a paraneoplastic origin is exceptional [31]. Brain MRI
generally shows cerebellar atrophy, exclusively in patients
with cerebellar ataxia without SPS [6, 30]. CSF analysis usu-
ally displays oligoclonal bands and intrathecal synthesis of
Table 1 The classification of immune-mediated cerebellar ataxias
1. Autoimmunity that mainly targets the cerebelluma or its related
structuresb:
Cerebellar autoimmunity not triggered by another disease:
Anti-GAD Abs associated cerebellar ataxia
Cerebellar type of Hashimoto’s encephalopathy
Primary autoimmune cerebellar ataxia
Others
Cerebellar autoimmunity triggered by another disease or condition:
Gluten ataxia (gluten sensitivity)
Acute cerebellitis (infection)
Miller Fisher syndrome (infection)
Paraneoplastic cerebellar degenerations (neoplasm)
2. Autoimmunity that simultaneously targets various parts of the CNS:
Multiple sclerosis
Ataxia in the context of connective tissue diseases such as SLE
aWhen cerebellar ataxias are sole or main symptoms, the cerebellum is
presumed to be the main target of autoimmunity
b For example, involvement of the proprioceptive spinocerebellar path-
way is assumed in Miller Fisher syndrome
c Paraneoplastic patients are exceptional
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GAD-Ab with normal cellularity and protein rate [6, 26]. Dis-
ease severity, phenotype, and response to treatment are not
correlated with serum or CSF GAD-Ab titers.
While SPS with GAD-Ab tends to respond favorably to
immunotherapy, cerebellar ataxia with GAD-Ab is usually
associated with a poor prognosis, most patients remaining
significantly disabled. Large-scale randomized studies are
lacking to determine the optimal therapeutic strategies in
GAD-Ab cerebellar ataxias. If corticosteroids are often disap-
pointing, intravenous immunoglobulins (IvIg) may have a
beneficial effect in some patients [29, 32].
Pathophysiology and mechanisms of neuronal dysfunc-
tions observed in patients with GAD-Ab are unknown. Some
studies suggest that, in contrast to GAD-Ab associated with
T1DM without neurological sign, GAD-Ab from patients
with neurological symptoms could be more than merely a
marker of autoimmunity and play a direct role in the develop-
ment of the disease [33, 34]. Indeed, intra-cerebellar or intra-
ventricular administration of IgGs from patients with GAD-
Ab and SPS or cerebellar ataxia blocks neuronal functions and
impairs synaptic regulation [33, 35]. Furthermore, mice im-
munization against GAD65 leads development of GAD-Ab
and GABAergic neuronal loss [36]. Interestingly, the effect of
GAD-Ab on neuronal functions seems to differ accordingly to
the neurological symptoms observed in patients. Indeed,
GAD-Ab from patients with cerebellar ataxia, contrarily to
GAD-Ab from SPS patients, do not inhibit GAD enzymatic
activity in vitro [24, 34]. Moreover, electrophysiological and
neurotransmitter levels alterations observed in rats treated
with intra-cerebellar and para-spinal infusions with IgGs from
GAD-Ab positive SPS are not observed with IgGs from pa-
tients with GAD-Ab positive cerebellar ataxia [34, 37]. On the
opposite, IgGs from patients with GAD-Ab positive cerebellar
ataxia are able to impair membrane turnover in GABAergic
neurons, suggesting an interference with GABA-containing
vesicles exocytosis [34]. These differences could be explained
by distinct epitope specificities recognized by GAD-Ab de-
pending on the patients. Even if GAD-Ab production is poly-
clonal in all patients, GAD-Ab recognize different epitopes
according to whether the associated syndrome is T1DM,
SPS or cerebellar ataxia [34]. The importance of such GAD-
Ab epitope specificities in the disruption of neuronal functions
is discussed in the next section. However, at this time, even if
many arguments suggest a pathophysiological role of GAD-
Ab, there is no clear demonstration that GAD-Ab alone are
able to provoke SPS or cerebellar ataxia. Some authors sug-
gested that other associated uncharacterized autoantibodies
might also play a role [36]. Cellular immunity could also play
a major role in patients with cerebellar ataxia [36]. Indeed,
peripheral T cells from patients with GAD-Ab and cerebellar
ataxia, but not SPS patients, increase their production of
INF-γ following exposition to GAD, suggesting a Th1 orien-
tation of those cells, a profile known to favor cytotoxicity [38].
To conclude, GAD65 is a particularly antigenic protein,
and GAD-Ab can be observed in different kinds of autoim-
mune disease or neurological syndromes where they probably
do not have the same clinical significance. GAD-Ab positivity
must not be interpreted alone, but in consideration with all
other potentially associated autoantibodies [29]. In the case
of neurological syndrome, intrathecal synthesis of GAD-Ab
is a strong argument for a potential role of these autoanti-
bodies, especially if the titer is low. Further works will be
necessary to understand the exact mechanisms of cerebellar
ataxia in patients with GAD-Ab.
Pathogenic Roles of GAD65 Antibodies (M. Manto
and CS. Hampe)
Unlike the isoform, GAD67, which is located in the cyto-
plasm, is constantly active, and produces a steady basal level
of GABA, the isoform GAD65 is mainly found associated
with synaptic vesicles, undergoes autoinactivation with at
least 50% of cellular GAD65 in the inactive apoenzyme form,
and generates pulses in GABA production when circum-
stances require a rapid synthesis and release [39, 40]. The
enzyme is necessary for the fine tuning of GABA-
concentrations in the vesicles and is also located on the cyto-
solic face of GABAergic vesicles in association with vesicular
GABA transporter (VGAT) [41] and other anchoring proteins,
such as NAP-22 [42]. The enzyme is involved both in GABA
transport into synaptic vesicles and in controlling synaptic
release of the neurotransmitter [35]. In GAD65 knockout
mice, the quantal size and frequency of GABA-mediated min-
iature inhibitory postsynaptic currents are normal, but evoked
GABAergic inhibitory post synaptic currents are reduced [43]
possibly contributing to the increased anxiety and propensity
for epilepsy observed in the animals [44]. It is currently pre-
sumed that the effects of GAD-Ab on GABA levels are medi-
ated by a direct inhibition of the enzymatic activity of GAD65
and an impairment of exocytosis of GABAergic vesicles.
The spectrum of autoimmune neurological deficits associ-
ated with GAD-Ab includes not only SPS, but also rare cases
of limbic encephalitis, epilepsy, and progressive cerebellar
ataxia [26, 45, 46]. Common comorbidities are T1DM and
autoimmune polyendocrine syndrome. Intrathecal production
of GAD-Ab has been reported in patients with stiff person
syndrome (SPS) [47], and GAD-Ab are typically found in
peripheral blood with lower concentrations in the CSF [48].
GAD-Ab titers do not necessarily correlate with disease se-
verity and cases with lower GAD-Ab levels have been report-
ed recently in ataxic patients [49]. Recent studies suggest that
the epitope specificity of GAD-Ab determine the pathogenic-
ity of the autoantibody (discussed in detail below). The path-
ophysiology of SPS includes decreased concentrations of
GABA in the brain and CSF [50] and inflammation in the
216 Cerebellum (2016) 15:213–232
CNS [45]. Cell loss has been demonstrated in ataxic patients,
with depletion of Purkinje neurons, Bergmann gliosis, and a
relative sparing of basket cells [51].
The direct pathogenic effects of GAD-Ab are still a matter
of debate [52]. Among the arguments against a direct patho-
genic role are: (1) the intracellular location of GAD65 making
it unlikely to illicit an antibody response, (2) the inaccessibil-
ity of intraneuronal GAD65 to its antibodies since neurons
have often been considered as Bimpermeable^ to immuno-
globulins, (3) the possibility that other Ab—or other undetect-
ed substances—present concomitantly in the serum might be
pathogenic. For the first issue, it can be argued that GAD65
could be exposed during exocytosis and thus provide a direct
opportunity for an interaction between Ab and antigen [53,
54]. For the second issue, it has been demonstrated that
Purkinje neurons (one key-target population of GAD-Ab in
the cerebellum) in rat organotypic cultures incorporate and
clear both host and non host immunoglobulin, even if the
antibodies do not recognize Purkinje cell antigens [55]. IgG
within Purkinje cells accumulates in cell nuclei and the cyto-
plasm. Moreover, kappa and lambda light chains in human
Purkinje neurons have been detected in a patient with multiple
myeloma [56]. The Purkinje neurons might thus be an excep-
tion to the rule of neuronal exclusion of antibodies. However,
the demonstration of uptake of a different SPS-associated au-
toantibody—directed to amphiphysin—by hippocampal neu-
rons [57] may indicate that neuronal uptake of immunoglob-
ulin is more frequent than previously recognized. The third
issue seems rather unlikely to occur with the use of monoclo-
nal GAD-Ab. Still, SPS is an example of a disorder where
autoantibodies other than GAD-Ab including anti-
amphiphysin, anti-GABA receptor-associated protein
(GABARAP) and anti-gephyrin Ab, can cause a similar phe-
notype, with each of these autoantigens being associated with
GABA-mediated neurotransmission [39].
Recent studies underline the importance of epitope speci-
ficity of GAD-Ab in the pathophysiology of GAD65-related
neurological disorders. As discussed in the previous section of
this publication, GAD-Ab are heterogeneous and target dis-
tinct epitopes of the enzyme. GAD-Ab in neurological disor-
ders recognize epitopes that differ significantly from those
found in patients with T1DM [58]. Importantly, GAD-Ab
present in SPS patients typically inhibit GAD65 enzyme ac-
tivity, a characteristic not observed for GAD-Ab found in
patients with T1DM [48]. Intrathecal passive transfer of
monoclonal GAD-Ab representing an epitope specificity char-
acteristic for SPS or purified immunoglobulin from sera from
GAD-Ab-positive SPS patients impair spinal cord activity,
induce a SPS-like syndrome with motor hyperexcitability,
change behavior, and cognitive operations [34, 35, 37, 59,
60]. GAD-Ab from ataxic patients suppress the release of
GABA and depress the inhibitory transmission long-lasting
time course [61]. In contrast, monoclonal GAD-Ab
representing an epitope specificity characteristic for T1DM
do not affect the activity of the enzyme [48] and do not inter-
fere with exocytosis [59]. This epitope-dependent effect of
neurological deficits induced by in vivo administration of
monoclonal GAD-Ab may explain why patients with T1DM
do not show neurological signs [33, 34, 37, 62].
In summary, despite accumulating in vitro and in vivo find-
ings arguing in favor of a direct pathogenic effect of GAD-Ab,
the debate is still alive. The unequivocal pathophysiological
demonstration is missing, at a moment where the critical roles
of antibodies for the diagnosis of GAD-Ab-related disorders
have been clearly accepted by the scientific community [63].
Cerebellar Type of Hashimoto’s
Encephalopathy-Diversity of Clinical Profiles (A.
Matsunaga and M. Yoneda)
Hashimoto’s Encephalopathy Hashimoto’s encephalopathy
(HE) is an autoimmune treatable encephalopathy associated
with chronic thyroiditis, and is distinct from myxedema-
encephalopathy associated with hypothyroidism [7, 64]. The
clinical entity and nosology of HE have been debated and the
reality of the illness questioned because of no evidence estab-
lishing a direct relationship between thyroid antibodies and en-
cephalopathy and the high prevalence of anti-thyroid antibodies
in the normal population. However, accumulated case reports
support the proposal of this autoimmune treatable disease, HE,
based on response to immunotherapy, pathologic findings of
brain tissue and presence of some autoantibodies [65].
HE patients present with a variety of neuropsychiatric
symptoms such as consciousness disturbance, psychosis, sei-
zures, cognitive impairment, involuntary movements, and cer-
ebellar ataxia [7, 66]. Some diagnostic criteria of HE have
been proposed as a combination of neurological and/or psy-
chiatric symptoms, elevated serum anti-thyroid antibodies
[Abs] (anti-thyroglobulin [TG] Abs and/or anti-thyroid perox-
idase [TPO] Abs) and responsiveness to steroid, associated in
part with abnormal EEG, normal brain imaging and elevated
proteins in CSF [7, 66]. Several autoantibodies relevant to HE
have recently been identified [65, 67, 68]. We discovered se-
rum autoantibodies against the NH2-terminal of α-enolase
(anti-NAE Abs) in patients with HE using a proteomics meth-
od [65, 67]. The anti-NAE Abs demonstrates high specificity
for HE, and can be a useful serological diagnostic marker for
HE [65, 67]. Although the pathogenesis of HE remains un-
clear, cerebral vasculitis was evident in the biopsied or post-
mortem brain tissue from HE patients [69, 70].
C e r e b e l l a r T y p e o f H a s h i m o t o ’ s
Encephalopathy Cerebellar ataxia is not a rare presentation
in HE [71] (28 % of patients observed by Matsunaga et al.,
unpublished data), and occasionally appears as an isolated or
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predominant symptom of HE (6 % of cases, [72]). We previ-
ously reported a patient with HE developing cerebellar ataxia
[73]. To clarify the characteristics of cerebellar type of HE, we
further investigated 13 patients, all of whom showed progres-
sive cerebellar ataxia as a predominant symptom, mimicking
degenerative CAs, and fulfilled the diagnostic criteria for HE
mentioned above [72]. In this investigation, all patients pre-
sented with truncal ataxia as a main symptom (100 %), but
nystagmus seldom appeared (17 %) [72]. Those patients who
presented with anti-NAE Abs tend to respond better to im-
mune therapy than anti-NAE Abs-negative patients [72].
Table 2 summarizes the reported cases showing cerebellar
ataxia as a predominant or isolated symptom in HE, including
our 13 cases reported previously [71–77]. The age of onset
ranged from 38 to 84 years old, and the male/female ratio was
8 to 10. Truncal ataxia is predominant in cerebellar symptoms.
The onset of cerebellar type of HE patients varied from acute
to chronic. The majority of the patients had an insidious onset
mimicking degenerative CAs [72, 73, 75, 77], whereas a few
patients presented with acute onset mimicking strokes [74,
76]. Serum anti-TG and/or anti-TPO Abs were detected in
all patients, and serum anti-NAE Abs was also detected in
some Japanese patients [72, 73, 76]. Most cases described in
the literatures showed elevated protein in CSF, while only one
of our 13 patients demonstrated elevated protein in CSF [72].
Although these cases presented with severe cerebellar ataxia,
the brain imaging showed little or no cerebellar atrophy except
for one case reported by Selim and Drachman [75]. Some
patients revealed diffuse slow waves on EEG as common
presentation in HE [7, 65, 66]. All patients responded to
Table 2 Comparison of clinical features of nonparaneoplastic immune-mediated cerebellar ataxia
GADa, n (%) HEb, n (%) Glutenc, n (%)
Total number 58 18 Epidemiology and symptoms; 68, Therapy; 26
Number of women (%) 50/58 (86) 10/18 (56) 33/68 (49)
Mean age (years) 58 years [26–79] 53 years 48 years [14–80]
Insidious onset 38/58 (66) 10/18 (56) Unknown
Cerebellar signs
Nystagmus 37/58 (64) 2/18 (11) 57/68 (84)
Dysarthria 38/58 (66) 11/18 (61) 45/68 (66)
Gait ataxia 55/58 (95) 17/18 (94) 68/68 (100)
Limb ataxia 41/58 (71) 13/18 (72) Upper 51/68 (75), Lower 61/68 (90)
Other symptoms SPS, limb stiffness, MG: 14/58 (24) Neuropsychiatric
symptoms: 11/18 (61)
Sensorimotor axonal neuropathy: 31/68 (45),
gluten-sensitive enteropathy: 16/68 (24),
gastrointestinal symptoms: 9/68 (13), focal
myoclonus, palatal tremor, and opsoconusa
Associated autoimmune diseases 45/58 (76), TDM1, thyroiditis,
hemolytic anemia
Common, Thyroiditis Common, thyroiditis, TDM1, pernicious anemia
Autoantibodies Anti-GAD-Ab
TPO, TG, ANA: 30/41 (73)
TPO, TG
NAE: 9/18 (50)
Anti-gliadin Ab, TG2 Ab, TG6 Abb
High proteins in CSF Unknown 6/18 (33) Unknown
Cerebellar atrophy on MRI 3/7 (43) 7/18 (39) 54/68 (79)
EEG Unknown Slow wave, 5/14 (36) Unknown




Gluten-free diet (or IVIg for cases with
gluten-free diet resistance c.), mycophenolate
for cases with myoclonic ataxia
Outcome
Complete remission 0/20 (0) 7/18 (39) 0/26 (0)
Partial remission 7/20 (35) 11/18 (61) 26/26 (100)
GAD anti-GAD-Abs-associated CA, HE cerebellar type of Hashimoto’s encephalopathy, gluten gluten ataxia, n number of patients
a Patients with GAD antibodies and cerebellar ataxia were evaluated using the series published by Honnorat et al. [6]; Saiz et al. [26], and Ariño et al.
[29]. One patient, reported in 2001, was excluded since 10 years after the publication she was found to have autosomique recessive ataxia [158]
b Patients with cerebellar type of HEwere evaluated based on the report byManto et al. [74, 145]; Selim et al. ([75], reported as Patient 5); Passarella et al.
[71]; Yamamoto et al. [76]; Tang et al. [77], and Matsunaga et al. [72]. TPO anti-thyroid peroxidase Ab, TG anti-thyroglobulin Ab, NAE anti-NH2-
terminal of α-enolase Ab
c Epidemiological and neurological symptoms were cited form the report of Hadjivassiliou et al. [79], and results of gluten-free diet were evaluated using
the report of Hadjivassiliou et al. [85]. (a) Sarrigiannis et al. [88], Kheder et al. [89], Deconinck et al. [90]. (b) Hadjivassiliou et al. ([84, 87] and [104]), (c)
Burk et al. [94]. TG2 Ab and TG6 Ab anti-transglutaminase 2 and 6 Abs
218 Cerebellum (2016) 15:213–232
immunotherapies except for one case reported by Yamamoto
et al. with spontaneous remission [76]. Furthermore, most
cases showed complete remission by administration of corti-
costeroids, few cases required immunoglobulin and/or im-
mune-suppressants. Recurrence of ataxia usually was appar-
ent when corticosteroids were tapered.
The pathological mechanisms underlying the develop-
ment of cerebellar ataxia in HE remain obscure. Recent-
ly, we examined the actions of the CSF obtained from
the 6 patients with ataxic HE using patch-clamp record-
ing from the rat cerebellar slices [78]. The CSF from one
patient, but not those of the other five patients, impaired
the presynaptic short-term plasticity between parallel
fiber-Purkinje cell transmissions. This result suggests that
defective glutamate release is a potential pathological
mechanism in some patients with HE.
In conclusion, cerebellar ataxia is a common presentation
in HE, characterized by truncal ataxia, little or absence of
cerebellar atrophy on brain imaging and good responsiveness
to steroid, which is recognized as Ba treatable ataxia^. It is
warrant that HE is one of the important differential diagnoses
for cerebellar ataxia after carefully excluding other causes.
Primary Autoimmune Cerebellar Ataxia
(M. Hadjivassiliou and P. Shanmugarajah)
In addition to specific cerebellar disease entities where auto-
immunity is triggered by another disease (e.g., cancer in
paraneoplastic cerebellar degeneration or gluten ingestion in
gluten ataxia) there is evidence to suggest that the cerebellum
can be a primary organ specific autoimmune disease, hence
the proposed term of Primary Autoimmune Cerebellar Ataxia
(PACA). This term implies no known trigger factor for the
development of immune-mediated damage to the cerebellum
a situation analogous to primary hypothyroidism
(Hashimoto’s disease), type 1 diabetes mellitus, vitiligo etc.
Evidence in support of such contention is diverse. Firstly,
the Human Lymphocyte Antigen (HLA) type DQ2 is signifi-
cantly overrepresented in patients with idiopathic sporadic
ataxia (74 % vs 35 % in the healthy population) whereas the
prevalence of this HLA type in patients with genetically char-
acterized ataxias is no different to the one found in the healthy
population [9]. The HLA DQ2 has been shown to have a
strong association with autoimmune diseases, such as celiac
disease and gluten ataxia, type 1 diabetes mellitus, stiff person
syndrome, autoimmune thyroid disease and autoimmune
polyendocrine syndromes [79–83]. Secondly there is a signif-
icantly higher prevalence of one or more autoimmune diseases
in patients with idiopathic sporadic ataxia when compared to
the general population and to patients with genetic ataxias (47,
3, and 5 %, respectively) [9]. In some cases, such association
prompted researchers to attribute the cerebellar dysfunction to
the presence of the other autoimmune disease [75]. Thirdly it
has been shown that cerebellar antibodies can be present in at
least 60 % of patients with idiopathic sporadic ataxia by con-
trast to 5 % in patients with genetic ataxias [9]. Figure 1 is an
example of the staining obtained using serum from a patient
with PACA on rat cerebellum. The autoimmune mechanism
by which the cerebellum is damaged in the context of autoim-
munity remains unclear. The presence of antibodies does not
necessarily imply antibody-mediated damage but may prove
to be a useful diagnostic aid. As the HLA DQ2 allele is found
in up to 35 % of healthy individuals, this test alone cannot
serve as a marker for PACA. The presence of additional auto-
immune diseases in either the patient or their first-degree rel-
atives may be another helpful pointer. Ultimately, characteri-
zation of the cerebellar antibodies may prove to be the best
diagnostic marker for PACA.
The next step in unraveling and consolidating PACA as a
disease entity is a trial of immunosuppression as a means of
treatment. Assessment of the value of immunosuppression in
these patients will be challenging. Firstly the choice, timing,
and duration of immunosuppression remain unclear. Second-
ly, monitoring treatment response may prove very difficult
because of the variable and mostly slowly progressive nature
of the disorder and the crude nature and poor sensitivity of
ataxia rating scales. MR spectroscopy of the cerebellum (ver-
mis and hemispheres) is proving to be an important and
Fig. 1 An example of the staining seen using sera (dilution of 1 in 600)
from a patient with primary autoimmune cerebellar ataxia on rat
cerebellum. There is clear staining of Purkinje cells as well as cells
within the granular layer. Such staining is not seen when using sera
from healthy controls or patients with genetic ataxia. The serum was
negative for all known Purkinje cell antibodies
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accurate tool in monitoring disease [84] and this may prove to
be a promising way of assessing treatment benefits.
While the final common pathological outcome in PACA, as
in other cerebellar ataxias, is the irreversible loss of Purkinje
cells, evidence derived from treatment of other immune-
mediated ataxias suggests that early intervention may not only
stabilize the ataxia but could also salvage malfunctioning cells
as evident by the demonstration of clinical and radiological
improvement of the ataxia [85].
The clinical characteristics of such patients may also assist
in case identification and in some cases distinguish from other
causes of ataxia. Patients with PACA tend to develop ataxia in
their early 50s. The ataxia in general, tends to be slowly pro-
gressive but in a few cases there may be a rather acute onset (a
picture not dissimilar to that often seen at presentation in
paraneoplastic cerebellar degeneration). In fact some of these
patients may have originally been diagnosed as having post
infectious cerebellitis, the difference being that they continue
to progress rather than improve. This pattern of organ involve-
ment is very similar to what is observed in Hashimoto’s thy-
roiditis. Subsequently, however such patients follow a much
more benign course with a very slowly progressive illness.
Additional autoimmune diseases may be already present or
may manifest subsequent to the development of the ataxia.
Patients with PACA almost always have cerebellar atrophy
on MRI but the severity of atrophy depends on disease dura-
tion. These patients are also easily distinguished from other
patients with sporadic late-onset ataxia such as patients with
cerebellar variant of multi-system atrophy by the absence of
autonomic involvement and the slower progression.
The next logical step in consolidating this disease entity is
an adequately powered study comparing immunosuppressive
treatment with placebo. The results of such a study will not
only clarify and consolidate the concept of PACA but will
hopefully offer hope for a substantial number of patients with
progressive sporadic Bidiopathic^ ataxia.
Gluten Ataxia (M. Hadjivassiliou)
Gluten ataxia (GA) was originally defined as otherwise idio-
pathic sporadic ataxia in the presence of circulating anti-
gliadin antibodies of IgG or IgA type [8]. This original defi-
nition was based on the serological tests available at the time.
The development of newer serological markers, more specific
to neurological manifestations (anti-TG6 antibodies) may as-
sist in improving the diagnosis but are not as yet readily avail-
able [86, 87]. In a series of over 1000 patients with progressive
cerebellar ataxia evaluated over a period of 20 years in Shef-
field, UK, GA had a prevalence of 15% among all ataxias and
41 % among idiopathic sporadic ataxias.
GA usually presents with pure cerebellar ataxia primarily
affecting gait and lower limbs. Rarely, it can present with
ataxia in combination with focal myoclonus [88], palatal trem-
or [89], or opsoclonus [90]. GA is usually of insidious onset
with a mean age at onset of 53 years. Pediatric cases, however,
have also been described [91]. Rarely, the ataxia can be rap-
idly progressive mimicking paraneoplastic cerebellar degen-
eration. Gaze-evoked nystagmus and other ocular signs of
cerebellar dysfunction are seen in up to 80 % of cases. All
patients have gait ataxia and the majority have lower limb
ataxia. Less than 10 % of patients with GA will have any
gastrointestinal symptoms and only 40 % will have evidence
of enteropathy on biopsy. As with celiac disease, patients with
GA are often found to have an increased prevalence of addi-
tional autoimmune diseases the commonest of which include
hypothyroidism, type 1 diabetes mellitus and pernicious ane-
mia. Gastrointestinal symptoms are seldom prominent and are
not a reliable indicator for the presence or absence of enterop-
athy. In this respect, gluten ataxia resembles dermatitis
herpetiformis, an autoimmune dermatopathy triggered by glu-
ten where gastrointestinal symptoms are not prominent even
in the presence of an enteropathy [92].
Up to 60 % of patients with gluten ataxia have evidence of
cerebellar atrophy on MR imaging but all patients have spec-
troscopic abnormalities (reduced N-acetylaspartate/creatinine)
primarily affecting the vermis (Fig. 2). Recent evidence sug-
gests that patients with newly diagnosed celiac disease (CD)
presenting to the gastroenterologists have abnormal MR spec-
troscopy at presentation and that this is also associated with
clinical evidence of cerebellar dysfunction (e.g., nystagmus,
gait ataxia) [93]. In addition, voxel-based morphometry and
volumetric analysis of the cerebellum reveal significant abnor-
malities in patients with CD when compared to age-matched
healthy individuals [93].
Response to treatment with a gluten-free diet depends on
the duration of the ataxia prior to the diagnosis. Loss of
Purkinje cells in the cerebellum, the end result of prolonged
gluten exposure in patients with GA, is irreversible and early
diagnosis and treatment is more likely to result in improve-
ment or stabilization of the ataxia. While the benefits of a
gluten-free diet in the treatment of patients with CD and der-
matitis herpetiformis have long been established, there are
very few studies of the effect of gluten-free diet on the neuro-
logical manifestations. Most are case reports primarily
concerning patients with established CD who then develop
neurological symptoms. Such studies suggest variable but
overall favorable responsiveness to a gluten-free diet. A small,
uncontrolled study looked at the use of intravenous immuno-
globulins in the treatment of four patients with GA without
enteropathy [94]. All patients improved. Only one systematic
study of the effect of gluten-free diet on a cohort of patients
presenting with ataxia, with or without an enteropathy, has
been published [85]. This study also reported serological ev-
idence of elimination of the anti-gliadin antibodies as a con-
firmation of strict adherence to the diet. Forty-three patients
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with gluten ataxia were enrolled. Twenty six adhered strict-
ly to the gluten-free diet, had serological evidence of
elimination of antibodies and comprised the treatment
group. Fourteen patients refused the diet and comprised
the control group. Patient and control groups were
matched at baseline for all variables (age, duration of
ataxia, etc.). There was no significant difference in the
baseline performance for each ataxia test between the
two groups. There was significant improvement in per-
formance in test scores and in the subjective global
clinical impression scale in the treatment group when
compared to the control group. The improvement was
apparent even after excluding patients with an enterop-
athy. The study concluded that gluten-free diet can be
an effective treatment for GA.
Patients with myoclonic ataxia and CD often have refrac-
tory enteropathy (non-responsive to the diet) and are at risk of
developing enteropathy associated lymphoma [88]. While
both the ataxia and enteropathy can be stabilized using immu-
nosuppressive treatment, the myoclonus remains the most dis-
abling feature of this condition which is poorly responsive to
symptomatic treatment (e.g., clonazepam, levetiracetam,
epilim, piracetam, etc.).
Patients presenting with ataxia due to celiac disease are
significantly older from those being diagnosed with CD by
the gastroenterologist (mean age 61 vs 47, respectively)
[95]. They are often more severely affected by their ataxia.
This is also reflected on imaging where the severity of atrophy
is marked and the spectroscopy values for N-acetylaspartate/
creatinine are low.
It is possible that the presence of gastrointestinal symptoms
in these patients offers a diagnostic advantage over patients
presenting with ataxia by making them more likely to be test-
ed for the disease and hence more likely to be diagnosed and
treated early.
Pathophysiology of Gluten Ataxia (M. Hadjivassiliou
and D. Aeschlimann)
There is strong evidence to suggest that the cerebellar insult inGA
is immune-mediated. Vitamin deficiencies (e.g., B12, E, copper)
are rarely implicated. Postmortem examination from patients with
gluten ataxia show patchy loss of Purkinje cells throughout the
cerebellar cortex [8, 96, 97]. The cerebellar white matter showed
astrocytic gliosis, vacuolation of the neuropil and a diffuse infil-
trate mainly of T-lymphocytes. In addition, there was perivascular
cuffing with inflammatory cells, mainly T-lymphocytes, with
smaller numbers of B-lymphocytes and macrophages.
Experimental evidence suggests that there is antibody
cross-reactivity between antigenic epitopes on Purkinje and
other cerebellar cells (granular layer) and gluten peptides.
For example, anti-gliadin antibodies have been shown to react
with human and rat cerebellar Purkinje cells in vitro [98].
However, sera from patients with gluten ataxia appear to con-
tain additional antibodies targeting Purkinje cell epitopes. This
is shown by the failure to eliminate such reactivity with
Purkinje cells when using sera from patients with gluten ataxia
after removal of anti-gliadin antibodies using crude gliadin.
There is increasing evidence of the involvement of
transglutaminases in the pathogenesis of GA [99, 100].
Transglutaminase 2, the autoantigen in celiac disease, is one
of a family of enzymes that covalently crosslink or modify
proteins. Gliadin proteins, the immunological trigger of gluten
Fig. 2 MR spectroscopy of the
vermis from a patient with gluten
ataxia. There is significant
reduction of NAA/Cr ratio (0.56,
normally should be above 1). This
is a typical finding in patients with
gluten ataxia even in the absence
of significant atrophy. Primarily
involvement of the vermis is also
seen in a number of other
immune-mediated ataxias in
contrast to degenerative and
genetic ataxias where there is
global involvement of the
cerebellum
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sensitivity, are glutamine rich donor substrates amenable to
deamidation [101]. TG2 may contribute to disease develop-
ment by deamidating gluten peptides and thereby increasing
their reactivity with HLA-DQ2/DQ8 (found in almost 100 %
of patients with CD) which potentiates the T cell response.
Why should these patients develop autoantibodies to TG2
remains unclear. The formation of complexes of gluten and
TG2 may permit gluten reactive T cells to provide the neces-
sary help to TG2-specific B cells. This would also explain
why serum antibodies to TG disappear when patients adopt
a gluten-free diet. However, it has also been suggested that
molecular mimicry, i.e., shared epitopes between deamidated
gliadin and TG2, or exposure of masked epitopes upon reac-
tion of the enzyme with antigenic gliadin peptides could lead
to autoantibody production [102].
Like TG2 in CD, TG3, an epidermal transglutaminase has
been shown to be the autoantigen in dermatitis herpetiformis
[103]. Dermatitis herpetiformis is a gluten-sensitive
dermatopathy that presents with an itchy vesicular rash and
is one example of extra-intestinal manifestations of gluten
sensitivity. While the majority of patients with dermatitis
herpetiformis have evidence of enteropathy on duodenal bi-
opsy, these patients rarely complain or present with gastroin-
testinal symptoms. This form of gluten sensitivity may be
determined by autoimmunity directed primarily toward TG3
rather than TG2 suggesting that the explanation for the het-
erogeneity in disease manifestation may lie in the specificity
of the immune response. Anti-TG3 antibodies have been
shown to induce pathology in an animal model mirroring that
of dermatitis herpetiformis, thus further emphasizing the cen-
tral role that antibodies or antibody complexes play in disease
establishment.
In an analogous way, TG6, a brain-expressed
transglutaminase has been shown to be a target antigen in
patients with GA [86]. Thus, patients with GA have evidence
of circulating anti-TG6 antibodies. Such antibodies are gluten
dependent and are eliminated by gluten-free diet [87]. TG6
antibodies isolated using phage display methods have been
shown to react with both Purkinje cells and cells within the
granular layer. Work on brain postmortem tissue of GA pa-
tients demonstrate the accumulation of IgA deposits in the
cerebellum and brainstem, most prominently within the mus-
cular layer surrounding vessels but also in brain tissue proper
[104]. Such intense perivascular changes may imply a
perivascular inflammation that compromises blood brain bar-
rier function and allows the entry of gluten related antibodies
into the central nervous system. Evidence that such anti-
bodies may potentially be pathogenic comes from mice
experiments [98]. Intraventricular injection of phage dis-
play produced antibodies against TG2 and TG6 were
capable of inducing ataxia in mice within 3 h of injec-
tion [99]. A similar observation was made using serum
from patients with gluten ataxia [99].
While a lot of insight as to the pathophysiology of gluten
ataxia can be gained from the above studies, there are still a
number of unanswered questions, namely the reason behind
the target of the autoimmune reaction (TG2 vs TG3 vs TG6 or
any combination) and ultimately the trigger for the develop-
ment of symptomatic disease in genetically susceptible
individuals.
Acute Cerebellitis (M. Hadjivassiliou)
Cerebellitis refers to an immune-mediated acute inflammation
of the cerebellum. It is generally thought to be the result of an
immune response to a recent infection (post infectious
cerebellitis) but it may at times represent the onset of primary
autoimmune cerebellar ataxia.
There have been numerous reports of acute ataxia due to
cerebellitis, predominantly in children, associated with specif-
ic infections, commonly viral illnesses such as influenza,
parainfluenza, varicella, mumps, measles, rubella, etc. Acute
cerebellitis has also been reported with bacterial infections
such as pertussus, typhoid, diphtheria, leptospirosis, myco-
plasma, Legionaires, etc. Post infectious cerebellitis makes
up 50 % of all neurological sequelae of varicella infection
and is thus very common in children [105]. In adults, the
commonest preceding infection is EBVor mycoplasma [106].
The clinical features are dominated by an acute onset of
cerebellar dysfunction, not infrequently associated with some
confusion or disorientation. Pediatric cases have a peak inci-
dence at 3 years of age with 34% having severe ataxia causing
inability to walk. The mean latency from onset of prodromal
illness to onset of ataxia is 9.9 days. Themean recovery period
is about 2 months with the majority of the patients (88 %)
making a full recovery [105]. In adult series, the clinical fea-
tures were similar with the addition of oculomotor distur-
bances in 73 %. The latency from onset of prodromal illness
to development of ataxia was longer at 3.5 weeks. CSF exam-
ination shows elevation of white cell count, predominantly
lymphocytes, in 50 % of patients and high protein in about
30 % of patients [106]. MRI may demonstrate cerebellar
swelling.
In those patients where recovery is incomplete (18 %),
there was cerebellar atrophy evident on MRI. These cases
may represent a subgroup of patients where acute cerebellitis
is a primary autoimmune phenomenon leading to permanent
and progressive ataxia, analogous to what is seen in
Hashimoto’s thyroiditis that can precede the onset of hypothy-
roidism [9].
While the use of DNA amplification techniques sometimes
reveal evidence of viral products in the CSF it is thought that
acute cerebellitis is in fact immunologically mediated. This is
supported by the specificity in the involvement of the cerebel-
lum with sparing of other parts of the brain, the presence of
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oligoclonal bands in some cases and generally good progno-
sis. One study demonstrated the presence of antineuronal an-
tibodies in acute cerebellitis following EBV infection [107].
Isolated case reports of fatal cerebellitis usually due to se-
vere swelling and brain herniation are rare and the only source
of pathology. The neuropathological findings seen in some of
these reports are compatible with an acute meningoencepha-
litis while other reports are more in favor of a post infectious
immune reaction similar to acute disseminated encephalomy-
elitis [108].
Cerebellar-like Ataxia in Miller Fisher Syndrome
and Related Conditions (N. Yuki)
In 1956, Miller Fisher described 3 cases of BAn unusual variant
of acute idiopathic polyneuritis (syndrome of ophthalmoplegia,
ataxia and areflexia)^ [109]. In 1962, Richter described the
Bataxic form of polyradiculoneuritis (Landry-Guillain-Barré
syndrome)^ characterized in a patient with profound ataxia
without weakness, no or minimal ophthalmoplegia, no sensory
loss (particularly for proprioception), and without a Romberg
sign [110]. The clinical presentation of ataxic Guillain-Barré
syndrome is very similar to Miller Fisher syndrome except for
the absence of ophthalmoplegia. In 1992, the seminal work by
Chiba and colleagues in discovering anti-GQ1b IgG antibodies
in patients with Miller Fisher syndrome led to the unraveling of
the pathogenesis of Miller Fisher syndrome and related condi-
tions [111]. Patients with ataxic Guillain-Barré syndrome, as
well as those with Miller Fisher syndrome, have been found
to carry anti-GQ1b IgG antibodies, suggesting that ataxic
Guillain-Barré syndrome is an incomplete form ofMiller Fisher
syndrome [112].
Anti-GQ1b antibodies are likely to have a pathogenic role
in the development of Miller Fisher syndrome and ataxic
Guillain-Barré syndrome based on the following findings: (i)
Antecedent infectious agents such as Campylobacter jejuni
and Haemophilus influenzae bear a GQ1b epitope [113,
114]; (ii) GQ1b is strongly expressed in the oculomotor
nerves, large-diameter dorsal ganglion neurons and muscle
spindles [115–117]; (iii) Human anti-GQ1b antibodies in the
presence of complement kill dorsal root ganglion neurons in
rats [118].
The site and nature of the pathophysiology of ataxia in
Miller Fisher syndrome have yet to be established because
there have been no autopsy reports of pure Miller Fisher syn-
drome. However, repeated nerve conduction studies have
shown that, at the least, the peripheral sensory nerve is one
of the sites, and the nature of the damage is axonal, not demy-
elinating [119]. Sensory nerve action potential amplitudes can
recover rapidly. This pattern of rapid reversibility, occurring
within weeks and without demyelinating features, suggests
dysfunction of the nodal and paranodal regions. In other
patients, slow progressive improvement or persistent changes
in sensory nerve action potential amplitudes represent axonal
degeneration. Based on the patterns of sensory abnormality,
the antigen target of the autoantibody attack may be in the
sensory nerves. Reversible conduction failure, as demonstrat-
ed in cutaneous afferents, is unlikely to be responsible for the
prominent ataxia in Miller Fisher syndrome. However, revers-
ible conduction failure may occur also in Ia afferents, which
are difficult to investigate in routine nerve conduction studies.
This may explain the rapid and generally complete recovery of
ataxia in Miller Fisher syndrome, which would be incompat-
ible with the exclusive involvement of dorsal root ganglia.
Some patients with Miller Fisher and Guillain-Barré syn-
dromes show striking limb incoordination with jerky rhythmi-
cal features not influenced by eye closure, no objective sen-
sory changes, and a negative Romberg test. Although neither
nystagmus nor cerebellar dysarthria were present, this form of
ataxia seemed to be of cerebellar origin [109, 110]. However,
Miller Fisher himself postulated that the Bcerebellar-like^
ataxia in these patients was of peripheral origin due to a
Bunique widespread and selective attack on the sensory neu-
rons underlying postural adjustment^ [109]. The only autopsy
study of ataxic Guillain-Barré syndrome showed no lesions in
the cerebellum but major degeneration of the fibers of the
posterior and Clarke columns without involvement of the neu-
rons of Clarke columns [110]. This suggested that Bcerebellar-
like^ ataxia is a consequence of the damage of afferent fibers
to the spinocerebellar system, although neither nerves nor
dorsal root ganglia had been sampled in the autopsy study.
Postural body sway analysis indicated selective involvement
of the Ia afferent system group in a patient with ataxic
Guillain-Barré syndrome who had anti-GQ1b antibodies, as
well as in patients with Miller Fisher syndrome [120, 121].
These findings suggest a dysfunctional proprioceptive afferent
system and that cerebellar-like sensory ataxia is caused by
selective involvement of muscle spindle afferents, as also
demonstrated by the absence of the H-reflex with normal sen-
sory conduction and normal sensory-evoked potentials.
Anti-GQ1b antibodies stain neural components and
intrafusal muscle fibers of spindles in mice, rats, and humans
[117], and mostly stain parvalbumin-positive nerves and puta-
tive nerve endings in rat muscle spindles, which provide evi-
dence that proprioceptive nerves highly express GQ1b [122].
IgG with anti-GQ1b reactivity from a patient with Guillain-
Barré syndrome bound to the nodes of Ranvier in human dor-
sal roots [123]. Antibodies to GQ1b also stain some large
neurons in human dorsal root ganglia [116]. MRI has shown
enhancing lesions in the spinocerebellar tracts at the level of
the lower medulla in a patient with Miller Fisher syndrome
overlapped by Guillain-Barré syndrome [124]. Overall, these
findings suggest that cerebellar-like ataxia described in some
Miller Fisher syndrome and ataxic Guillain-Barré syndrome
patients may be caused by selective involvement of group Ia
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afferents along their path from muscle spindles to spinal cord,
or involvement of the proprioceptive spinocerebellar pathway.
Paraneoplastic Cerebellar Degenerations (B. Joubert
and J. Honnorat)
Paraneoplastic neurological syndromes (PNSs) are rare neu-
rological diseases representing a remote effect of a cancer
[125]. By definition, they cannot be explained by metastatic,
metabolic, iatrogenic, or infectious causes. Paraneoplastic cer-
ebellar degenerations (PCDs) are the most frequent PNS,
making up to 24 % of the reported PNSs [126].
Patients with PCDs present with symmetrically distributed
static and kinetic cerebellar symptoms. Symptoms usually in-
stall subacutely in a few weeks or months, although fast,
stroke-like presentations may as well occur. Extracerebellar
symptoms can be occasionally present, expressing additional
involvement of limbic regions, brainstem, spinal cord or dor-
sal root ganglia [127], but cerebellar ataxia is isolated in most
of the cases. In 84 % of the patients, the neurological syn-
drome precedes the discovery of the underlying tumor [5,
127]. CSF analysis may display mild lymphocytosis, in-
creased proteins, and/or oligoclonal bands. Brain MRI is usu-
ally normal at the onset of the disease and cerebellar atrophy,
preferentially involving the vermis, may appear only at later
stages. Alternative diagnoses must be cautiously excluded. A
cerebellar tumor, stroke, or a metabolic disease are usually
easily ruled out, while leptomeningeal metastasis, late-onset
degenerative cerebellar atrophy, infectious cerebellitis, and
chemotherapy adverse effects can be difficult to distinguish
from a paraneoplastic etiology.
Most PCDs associate with the so-called onconeural antibod-
ies (ONA), such as anti-Hu, anti-Yo, anti-CV2/CRMP5, anti-
Ma2, anti-Ri, or anti-Tr/DNER antibodies [127] (Table 3).
Those autoantibodies target intracellular neuronal antigens that
are ectopically expressed by the tumor [128]. They are found in
80 % of PCDs patients, emphasizing the probable autoimmune
origin of this disease [5]. Most rarely PCDs have been de-
scribed in patients with SCLC and anti-VGCC antibodies.
A cancer is found in up to 84 % of ataxic patients with
serum ONA, gynecologic cancers (breast, ovaries, uterus),
small cell lung carcinoma and Hodgkin’s lymphoma being
the most frequent [127]. Each autoantibody associates with
specific tumor types [127] and therefore the nature of the
antibody guides the search for the causative cancer
(Table 2). Whole body Computed tomography (CT) scan,
pelvic ultrasonography, and mammography are essential
first-line tests. Whole-body FDG positron photon emission
computed tomography (PET) scanner examinations greatly
improve cancer detection in PNSs [129]. In rapidly evolving
and severe cerebellar ataxia, exploratory laparotomy in wom-
en with anti-Yo antibody, or orchidectomy in male patients
with anti-Ma2 antibodies, may be necessary in order to detect
microscopic tumors [130, 131]. If inconclusive, investigations
must be repeated at a regular basis.
The pathophysiological function of ONA is still under de-
bate. They may not play a role by themselves but probably
only act as a biological marker of the autoimmune process.
The observed Purkinje cells death is supposed to be mainly
due to a cell-mediated cytotoxic immune response. Indeed,
circulating activated CD8+ T cells specific for Yo or HuD
antigens have been found in PCDs patients with such autoan-
tibodies [132]. Brain biopsies and autopsies have shown the
presence of CD8+ T cells infiltrates and activated microglia in
the cerebellum associated to a profound loss of Purkinje cells,
while B cells, IgG, or complement could not be detected [133].
On the other hand, anti-Yo antibodies incubated ex vivo with
cerebellar slices are actively internalized by Purkinje cells, and
significantly increase neuronal death, suggesting that those
Table 3 Frequency, clinical features and cancer associations of PCDs associated onconeural antibodies
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Frequency among PCDs was evaluated based on the report by Shams’ili et al. [127]
SCLC small cell lung cancer, PEM paraneoplastic encephalomyelitis, SN sensory neuronopathy, LE limbic encephalitis, OM opsoclonus-myoclonus,
LEMS Lambert-Eaton myasthenic syndrome
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specific autoantibodies may play some role in the disease
[134]. Nevertheless, various experiments, including the injec-
tion of patients’ antibodies, the immunization of murine model
with purified Yo or HuD antigens, and activated T cells injec-
tions failed to create an animal model of PCDs [135, 136].
Patients’ outcome is usually poor. Due to the diffuse neu-
ronal loss, neurological improvement is rare, and treatments
allow only for a stabilization of the symptoms. Tumor removal
and physiotherapy are currently the cornerstone of the treat-
ment. Immunotherapy is often disappointing, likely due to the
early neuronal death. Because of the rarity of PCDs, there is to
date no large-scale clinical study in this field. A few retrospec-
tive studies and case reports have suggested a beneficial effect
of corticosteroids and intravenous immunoglobulins (IvIg) in
some patients with anti-Hu or anti-Yo antibodies. Therefore,
there may be subgroups of patients with a better response to
immunotherapy, although their distinctive features remain to
be defined. Prognosis also varies depending on the nature of
the associated ONA. For instance, anti-Tr associated PCD are
particularly remarkable for the improvement observed after
efficient treatment of the associated lymphoma, irrespective
of additional immunotherapy [137].
It has to be noted that cerebellar ataxia is exceptionally
associated with antibodies targeting synaptic antigens, such
as the metabotropic glutamate receptormGluR1 [138]. In such
cases, tumors are infrequent and immunotherapy is usually
efficient, due to the fact that symptoms are likely due to a
direct and reversible functional effect of the autoantibodies
themselves on synaptic transmission.
Future studies are needed in order to clarify the respective
role of autoantibodies and cytotoxic T cells in the develop-
ment of PCDs, as well as to define optimal therapeutic strat-
egies for this debilitating disease.
Ataxia Associated with SLE (P. Chattopadhyay
and K. Adhikari)
In lupus, the most common cause of acute ataxia is damage to
cerebellum either due to the disease activity itself as part of
neuropsychiatric systemic lupus erythematosus (NPSLE) or
can be secondary due to acute disseminated encephalomyeli-
tis, drug-related inflammatory damage, vasculitis or atypical
infections [139, 140]. Secondary causes are twice as common
as primary NPSLE and the treatment strategies are very dif-
ferent [141].
Cerebellar involvement in SLE is rare occurring in less
than 2 % of cases [142–148]. Like in multiple sclerosis, the
immunological mechanisms responsible are not specific to the
cerebellum and usually affect other parts of the central and
peripheral nervous system. Females in reproductive age group
are primarily involved. The clinical features of ataxia depend
on the pathogenic mechanism as well as the part of cerebellar
and its connection involved. Acute ataxia in lupus may be
either a focal involvement- due to vaso-occlusion due vascu-
lopathy (mainly small vessel), vasculitis, leuco-aggregation or
thrombosis resulting in ischemia, infarction, hemorrhage or
vasogenic edema; or a diffuse cerebellar involvement- due to
different antibodies such as anti-DsDNA, cross reacting to
brain NMDA receptors mediating cerebellar injury or dys-
function. Other causative factors may be excitotoxicity, dif-
fuse endothelial injury, and leucothrombosis in microvascula-
ture mimicking Schwartzmann phenomenon, resulting from
intravascular complement activation leading to leucocytes
and platelet adhesion with endothelium [149]. Focal involve-
ment present with ipsilateral limb and ocular ataxia with cere-
bellar hemispheric signs, often with neurologic signatures of
associated brainstem involvement. Diffuse involvement on the
other hand present with acute/subacute pancerebellar symptoms
of bilateral limb, gait, and ocular ataxia often in isolation with-
out other supporting neurologic findings [147, 148].
Thromboembolism and hypercoagulability resulting in
microinfarcts and small vessel vasculopathy is the most com-
mon pathological substrate of NPSLE. Macroinfarcts, micro
or macrohemorrhages, cortical atrophy, demyelination, true
vasculitis has also been described [149, 150].
MRI is the investigation of choice [140]. Conventional
MRI may reveal diffuse cerebellar atrophy and volume loss
along with diffuse cerebral, corpus callosal and hippocampal
atrophy, although periventricular and subcortical white matter
lesions indicative of edema and small infarct are most com-
mon MRI findings. Data related to cerebellar involvement in
lupus are sparse though cerebellar changes are associated with
neurocognitive deficits in other inflammatory and ischemic
diseases. In pediatric lupus patients, cerebral and cerebellar
volume loss is maximum in patients with NPSLE in the first
4 years of disease presentation [151]. Cerebellar, cerebral, and
corpus callosal atrophy are present in newly diagnosed pa-
tients with NPSLE, possibly indicating sequel of active
neurolupus rather than effect on cumulative steroid dosage.
Patients with previous nephritis have less prominent volume
loss indicating control of neuro-inflammation as these patients
have already received immunosuppressive therapy [151].
Functional studies such as PET or single photon emission
computed tomography (SPECT) scan may reveal patchy areas
of dysfunction in brain areas unaffected in conventional MRI
suggesting an uncoupling of cerebellar metabolism unrelated
to obstruction of blood flow.
Management will be expectant with minimum intervention
in mild CNS disease, as opposed to focal or diffuse severe
CNS syndromes which require urgent intervention. Symptom-
atic therapy, anticoagulants, and immunosuppressive treat-
ments are cornerstones of therapy. Apart from different stroke
episodes, which require either stroke prevention with anti-
thrombotic therapy or control of hypertension, other acute
cases of cerebellar ataxia often require immunologic
Cerebellum (2016) 15:213–232 225
modification mainly augmentation of steroid and or intrave-
nous cyclophosphamide therapy. High-dose intravenous
methyl prednisolone therapy is often effective, reversing the
MRI abnormality followed by clinical improvement [148].
Reversibility of Immune-Mediated Cerebellar
Ataxia: How Impaired are the Cerebellar Predictive
Control Mechanisms? (S. Kakei, J. Lee, K. Nanri
and H. Mizusawa)
Whenwemake a reaching movement, there are infinite possible
combinations of muscle activities that could produce the same
movement kinematics, due to the redundancy of the musculo-
skeletal system (see, e.g., [152] for a review). Nevertheless,
muscle activities are usually stereotyped, suggesting that there
is a hidden constraint why the controller chooses a particular
pattern. The constraint, if identified in both health and neurolog-
ical disorders, could provide valuable information to provide
pathophysiological explanations for movement disorders.
Therefore, it is desirable to develop a method to functionally
characterize diverse patterns of muscle activities [153, 154].
Recently, we developed a novel method to characterize pat-
terns of muscle activities in terms of their similarities to com-
ponents of movement kinematics [154]. In this method, we
determine a symmetric relationship between the linear sum of
activities of the four wrist prime movers and the second-order
linear equation of motion for the wrist joint in terms of the joint
torque. The symmetric relationship determines a set of param-
eters that characterize the muscle activities by quantifying their
similarity to the components of movement kinematics of the
wrist joint. Recently, we applied this method to compare func-
tional characteristics of muscle activities of immune-mediated
CAs, degenerative CAs, and age-matched normal controls.
The six patients with immune-mediated CAs (three patients
with anti-GAD-Ab associated CA, two with gluten ataxia, and
one patient with cerebellar type of Hashimoto’s encephalopa-
thy) included three males and three females, with a mean age
of 66.6±7.2 years (±SD), with a mean disease duration of 6.2
±6.4 years. With regard to activities of daily living, three
patients walked without assistance while three used walkers.
These patients showed clinical improvement following immu-
notherapy. The ICARS of 23.4±15.5 improved to 14.8±13.6.
Two patients exhibited distinct cerebellar atrophy. Whereas
three patients showed mild cerebellar atrophy and the cerebel-
lum was normal in one patient. Furthermore, these four pa-
tients showed no obvious atrophy of the white matter on MRI
voxel-based morphometry. The study also included eight pa-
tients with degenerative CAs (five patients with multiple sys-
tem atrophy and three patients with spinocerebellar ataxia 6;
four males and four females, mean age, 64.2±10.5 years),
with a mean disease duration of 4.8±2.3 years. Five of these
patients walked without assistance, two used walkers, and one
patient was wheelchair-dependent. The present study also in-
cluded nine normal control subjects (six males and six fe-
males, mean age, 61.9±8.8 years) free of neurological
abnormalities.
We asked the subjects to perform a smooth tracking move-
ment of the wrist joint with a manipulandum (Fig. 1a in [154]).
They were required to maintain the position of the cursor
within a target moving smoothly along a path of the Fig. 2
at a constant slow speed [154]. We evaluated accuracy of
movement with a tracking score. The tracking score represents
how much time (in %) the subject keeps the cursor within the
target from start to the end of a trial. During the task, we
recorded the wrist position (X and Y) and surface EMG signals
of the four wrist prime movers (extensor carpi radialis, exten-
sor carpi ulnaris, flexor carpi ulnaris, and flexor carpi radialis
muscles) at 2 kHz [154].
We approximated a relationship between EMG signals of
the four wrist prime movers and movement kinematics with
the Eq. (1) (simplified from [154]).
τ tð Þ ¼
X4
i¼1
aiT i tð Þ ¼ M θ¨ tð Þ þ Bθ˙ tð Þ þ Kθ tð Þ ð1Þ
where, τ(t) denotes the wrist joint torque calculated from the
wrist joint kinematics. Ti represents the tension of eachmuscle
and ai denotes parameters that convert the muscle tension into
the wrist joint torque. The variables θ(t), θ˙ tð Þ and θ¨ tð Þ repre-
sent angle, angular velocity, and angular acceleration of the
wrist joint. M, B, and K represent the inertia [kg m2], the
viscous coefficient [N m s/rad] and the elastic coefficient
[N m/rad] for the wrist joint. We searched for the combination
of B and K that yielded the best match for the Eq. (1). Impor-
tantly, the best symmetric relationship was obtained when B
was in a specific ratio toK (see Fig. 4 in [154]). Thus, we used
the B/K ratio as a parameter to characterize the muscle activ-
ities in terms of the movement kinematics.
We calculated the B/K ratio to characterize the muscle activ-
ities in terms of the movement kinematics for the normal con-
trols, the patients with degenerative CAs and the patients with
immune-mediated CAs. The control subjects were capable to
follow themoving target smoothly with high accuracy (tracking
score 93–100 %, m±sd=97.8±2.3, n=8). Their B/K ratios
ranged from 1.34 to 1.85 (m±sd=1.59±0.18, n=8) (Fig. 3),
suggesting that their muscle activities were weighted compara-
bly or more for velocity control than for position control of the
wrist joint. In contrast, B/K ratios for the degenerative CA pa-
tients were much lower (0.68–1.20, 0.83±0.28, n=8) (p<1.4×
10−5, Student’s t test), suggesting that the muscle activities of
the degenerative CA patients contained much less component
for velocity control. The lower weight for smooth velocity con-
trol may explain rough movement kinematics (Fig. 4 in [154])
and poor accuracy (Fig. 3) (19–89 %, 60.5±25.6, n=8)
(p<0.001) of the tracking in the patients with degenerative
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CAs. On the other hand, for the patients with immune-mediated
CAs, accuracy of tracking was as poor (26.4–84.9 %, 59.68±
29.4, n=6) (p>0.95) as the patients with degenerative CAs
(Fig. 3). Nevertheless, their B/K ratios were comparable or even
higher (1.19–2.95, 1.75±0.64, n=6) (p>0.49) than that of nor-
mal controls, suggesting that ability to generate muscle activi-
ties for velocity control was more preserved in the patients with
immune-mediated cerebellar ataxia than in the patients with
degenerative CAs.
In the task employed in this study, it was necessary to
control both velocity and position of the wrist joint to track
the moving target accurately. In accordance with this require-
ment, both velocity and position were comparably encoded in
the muscle activities of the normal controls as was represented
in their B/K ratios (Fig. 3, open circles). In contrast, for the
patients with degenerative CAs, B/K ratios were significantly
lower than the normal controls, suggesting a relative lack of
velocity control (Fig. 3, red symbols). Consequently, tracking
accuracy of the degenerative CA patients was much poorer
than the control subjects (Fig. 3). On the other hand, in the
case of the patients with immune-mediated CAs, their move-
ment kinematics appeared as ataxic as that of the patients with
degenerative CAs. Nevertheless, their B/K ratios remained
comparable to those of the normal controls (Fig. 3, blue sym-
bols). How can we interpret the striking contrast of B/K ratios
in the two groups of patients with ataxia? In degenerative CA
patients, the relative lack of velocity control is basically
irreversible due to degeneration of cerebellar neurons. On
the other hand, in patients with immune-mediated CAs, the
velocity control appears to remain functional at least in early
phase, although its accuracy is deteriorated considerably. Fur-
thermore, a part of the deficit appears to remain reversible
because they are sometimes treatable [32, 49, 61, 155, 156].
The contrasting changes in B/K ratios for the immune-
mediated CAs and the degenerative CAs might be explained
as follows. In patients with degenerative CA, outputs from
Purkinje cells (PCs) are lost due to severe loss of PCs. By
contrast, in the patients with immune-mediated CAs, outputs
from PCs are inadequately augmented, at least initially, due to
blockade of strong GABAergic inhibition frommolecular lay-
er interneurons (most notably basket cells) [61]. In both con-
ditions, the cerebellum might well generate erroneous predic-
tions because of insertion of virtual errors [157], although in
different manners. In conclusion, analysis of B/K ratio in atax-
ic patients may provide a unique and useful clue to find po-
tentially treatable ataxias.
Conclusion (H. Mitoma)
In this consensus paper, we have attempted to capture the
diversity of the clinical features and proposed pathological
mechanisms of immune-mediated cerebellar ataxias (CAs),
by gathering contributions from an international panel of ex-
perts. The main points of the consensus based on various areas
of discussion of immune-mediated ataxias include the
following:
Clinical Features In addition to the classical immune-
mediated diseases (paraneoplastic cerebellar degeneration,
Mi l le r F isher syndrome) , the c l in ica l en t i ty of
nonparaneoplastic immune-mediated CAs has been
established recently. This includes anti-GAD-Abs associated
CA, cerebellar type of Hashimoto’s encephalopathy, primary
autoimmune cerebellar ataxia (PACA), and gluten ataxia. The
clinical features of these diseases are summarized in Table 3.
Diverse Pathomechanisms Vasculitis is presumed to be the
main pathological mechanism of Hashimoto’s encephalopa-
thy and ataxia in systemic lupus erythematosus. In
paraneoplastic cerebellar degeneration, cell-mediated autoim-
munity is likely responsible for CAs, and autoantibodies are
considered to be the marker, not the pathogenic agent. On the
other hand, the pathogenic roles of autoantibodies have been
suggested in anti-GAD-Abs associated CA and Miller Fisher
syndrome, and probably also in gluten ataxia. Taken together,
it is possible that various forms of autoimmunity operate in
immune-mediated diseases, resulting in the development of
CAs. Disease-specific mechanisms of the autoimmunity re-
quire further clarification.
Fig. 3 Relationship between the B/K ratio of predictive motor command
and tracking score. Circles represent the normal control subjects. Red
symbols represent the patients with degenerative CAs. Blue symbols rep-
resent the patients with immune-mediated CAs. MSA multiple systemic
atrophy, SCA6 spinocerebellar ataxia type 6, anti-GAD anti-glutamic acid
decarboxylase (GAD) antibody associated cerebellar ataxia, gluten gluten
ataxia, HE cerebellar type of Hashimoto’s encephalopathy
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Reversibility and Treatable ataxias By using recent ad-
vances in physiological methods, the ratio of feed-forward
or feed-back controls can be determined. The operation of
feed-forward control could be an index for the survival of
cerebellar function. Interestingly, the motor control in patients
with immune-mediated CAs was in contrast to that in patients
with degenerative CAs, although both patients similarly
showed clumsiness in tracking tasks. In the former, feed-
forward control is still present, although its property is not
exact, whereas in the latter feed-forward control is abolished
and, instead, feed-back control is compensatively operational
(Fig. 4). The survival of feed-forward controls could be a
physiological evidence for reversibility and treatable feature
of immune-mediated CAs, suggesting the importance of early
diagnosis and immune therapy.
Historically, the establishment of the new disease entity has
highlighted the hidden role of the cerebellum in motor control.
In the beginning of twentieth century, differentiation of degen-
erative CAs, e.g., olivo-ponto-cerebellar atrophy, from dorsal
column ataxias led to the beginning of neurology of the cere-
bellum. After World War I, comprehensive studies on trauma
of the cerebellum widened the understanding of coordination
and dysmetria. Similarly, further studies on immune-mediated
CAs might open a new page of cerebellar symptomatology,
especially about how the acquired functions by the cerebellum
are disrupted.
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